News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 17, 2023
Mediation analyses of finerenone trial data show most of the drug’s kidney benefit and a third of its CVD benefit comes from cutting albuminuria.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 14, 2023
The 2021 race-free CKD-EPI equation for estimating glomerular filtration rate outperformed two alternative formulas in adults aged 18-40 years.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 9, 2023
Klinrisk, which estimates an adult’s risk for CKD progression from 20 lab values, may spur more targeted, intensified treatment.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 7, 2023
Aprocitentan, a novel dual endothelin antagonist, showed antihypertensive efficacy and manageable safety in people with chronic kidney disease.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: November 6, 2023
An EMR prompt in primary care to measure albuminuria and eGFR in adults with type 2 diabetes boosted screening by about 50%.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: October 26, 2023
“These findings may provide valuable information to clinicians and people with type 2 diabetes regarding the likelihood of achieving substantial bo...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: September 28, 2023
The second addition concerns a new adverse reaction that was identified during the postmarketing experience: gastrointestinal ileus, an intestinal ...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: September 22, 2023
“MPI has been around for many years, but our technique is rather novel” and has high intra- and inter-observer reproducibility. “It’s highly reprod...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: September 22, 2023
“The data show concerning safety signals that need further investigation.”
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: September 8, 2023
Dapagliflozin appeared to improve diuresis and natriuresis while reducing the administered diuretic dose.
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 30, 2023
The study tested a “very simple” symptom questionnaire as the initial screening phase, yet resulted in a CVD diagnostic rate that was two- to three...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 29, 2023
“The outcomes we’ve already seen in STEP-HFpEF were largely symptomatic, which are extraordinarily important, but there may be a completely differe...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 28, 2023
Another major change in the new ESC guideline revision is introduction of a CVD risk calculator intended to estimate the risk among people with typ...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 25, 2023
The normalization in associative learning that one dose of liraglutide produced in people with obesity “fits with studies showing that these drugs ...
News
- Author:
- Mitchel L. Zoler, PhD
Publish date: August 25, 2023
The results “indicate that treatment with semaglutide is a valuable therapeutic approach in the management of patients with HFpEF and obesity.”
